Lista de obras - Jacek Borawski - Dominio Público Uruguay

Activation of hepatocyte growth factor/activin A/follistatin system during hemodialysis: role of heparin

artículo científico publicado en 2003

Activin A/follistatin system: another link to heparin-induced osteoporosis?

artículo científico publicado en 2004

Altered circadian rhythm of platelet aggregation in hemodialyzed patients

artículo científico publicado en 1997

Chronic viral hepatitis C, oxidative stress and the coagulation/fibrinolysis system in haemodialysis patients

scientific article published on 02 May 2008

Circulating endothelial markers and probability of stroke in haemodialysis patients

artículo científico publicado en 2003

Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study

artículo científico publicado en 2003

Effect of hemodialysis on plasma levels of vascular endothelial markers

artículo científico publicado en 2002

Effect of ketanserin on platelet function and bleeding time in uremic patients treated with erythropoietin.

artículo científico publicado en 1995

Effect of sulodexide on plasma transforming growth factor-beta1 in healthy volunteers.

artículo científico publicado en 2008

Effects of Enoxaparin on Intravascular Sclerostin Release in Healthy Men.

artículo científico publicado en 2018

Effects of enoxaparin on myeloperoxidase release during hemodialysis

scientific article published on 19 May 2014

Effects of recombinant erythropoietin therapy on circulating endothelial markers in hemodialysis patients.

artículo científico publicado en 2002

Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase response

artículo científico publicado en 2001

Endothelial injury markers with high-dose intravenous iron therapy in renal failure

artículo científico publicado en 2004

Enoxaparin but not unfractionated heparin causes a dose-dependent increase in plasma TGF- 1 during haemodialysis: a cross-over study

artículo científico publicado en 2007

Enoxaparin decreases serum MCP-1 concentration during haemodialysis-preliminary report

artículo científico publicado en 2009

Evaluation of the thyroid size among school children aged 6-13 with the normal iodine excretion in the urine and the usability of referential values still applied

artículo científico publicado en 2005

Extracellular superoxide dismutase release by enoxaparin and sparing effect of heparin-grafted hemodialyzer

artículo científico publicado en 2015

Full-length TFPI release by heparinoid sulodexide

artículo científico publicado en 2010

Hemoglobin level is an important determinant of acid-base status in hemodialysis patients

artículo científico publicado en 2002

Heparin, Myeloperoxidase, and Atherosclerosis

scientific article published on 01 April 2007

Hepatocyte Growth Factor: A Possible Mediator of Heparin-induced Osteoporosis?

artículo científico publicado en 2003

Hepatocyte growth factor in saliva is a potential marker of symptomatic periodontal disease

artículo científico publicado en 2006

Hepatocyte growth factor in saliva of patients with renal failure and periodontal disease

artículo científico publicado en 2012

Hepatocyte growth factor/activin A/follistatin system activation during hemodialysis with different low molecular weight heparins.

artículo científico publicado en 2009

High plasma endostatin level unaffected by low-molecular weight heparin in hemodialysis patients--a preliminary report.

artículo científico publicado en 2009

Increased soluble thrombomodulin does not always indicate endothelial injury

artículo científico publicado en 2002

Inflammatory markers and platelet aggregation tests as predictors of hemoglobin and endogenous erythropoietin levels in hemodialysis patients

scientific article published on 01 August 2002

Insulin sensitivity, plasma adiponectin and sICAM-1 concentrations in patients with subclinical hypothyroidism: response to levothyroxine therapy

artículo científico publicado en 2011

Intravenous and oral sulodexide versus coagulation activation markers in humans.

artículo científico publicado en 2009

Inverse relationships between haemoglobin and ristocetin-induced platelet aggregation in haemodialysis patients under erythropoietin therapy

scientific article published on 01 December 1996

Is xerostomia a risk factor for cardiovascular morbidity and mortality in maintenance hemodialysis patients?

artículo científico publicado en 2012

Ketanserin and erythropoiesis in hemodialysis patients with polycystic kidneys

artículo científico publicado en 1996

Liver disease vs systemic inflammation in haemodialysis patients

artículo científico publicado en 2005

Long-term effects of erythropoietin on platelet serotonin storage and platelet aggregation in hemodialysis patients with reference to ketanserin treatment.

artículo científico publicado en 1998

Modulation of hematopoiesis by ketanserin in erythropoietin-treated uremic patients: evidence from platelet studies

scientific article published on 01 January 1998

Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: the underestimated modifying effects of heparin.

artículo científico publicado en 2006

Myeloperoxidase up-regulation during haemodialysis: is heparin the missing link?

artículo científico publicado en 2006

Plasma activin A in hemodialysis patients: does brand of immunoassay matter?

artículo científico publicado en 2004

Plasma fibrinogen level is an important determinant of prolonged euglobulin clot lysis time in hemodialysis patients.

artículo científico publicado en 2001

Pleiotropic effects of heparin and heparinoids in peritoneal dialysis.

artículo científico publicado en 2007

Problems of nephrooncology. Proceedings from the 1st Scientific and Training Conference Nephrooncology 5-6 October 2018, Gdańsk, Poland.

artículo científico publicado en 2019

Relations between oxidative stress, hepatocyte growth factor, and liver disease in hemodialysis patients

artículo científico publicado en 2002

Relationship between oxidative stress and extrinsic coagulation pathway in haemodialyzed patients

scientific article published on 01 March 2003

Relevance of some growth factors to cardiovascular disease in maintenance hemodialysis patients

artículo científico publicado en 2006

Renal function, proteinuria and ACE‐inhibitor therapy as determinants of plasma levels of endothelial markers

artículo científico publicado en 2002

SEN virus infection in maintenance hemodialysis patients

artículo científico publicado en 2006

Salivary phosphate-binding chewing gum--an integrative approach to chronic kidney disease and oral diseases

artículo científico publicado el 1 de enero de 2011

Serum alpha1-antitrypsin but not complement C3 and C4 predicts chronic inflammation in hemodialysis patients

artículo científico publicado en 2003

Serum hepatocyte growth factor is associated with viral hepatitis, cardiovascular disease, erythropoietin treatment, and type of heparin in haemodialysis patients.

artículo científico publicado en 2002

Short-term Erythropoietin Therapy Does Not Increase Plasma Tissue Factor and its Inhibitor Levels in Hemodialysis Patients

scientific article published on 01 April 2003

Staphylococcal scalded skin syndrome in the course of lupus nephritis

artículo científico publicado en 2008

Striking increase in circulating hepatocyte growth factor during enoxaparin-anticoagulated haemodialysis

artículo científico publicado en 2003

Sulodexide for hemodialysis anticoagulation in heparin-induced thrombocytopenia type II.

artículo científico publicado en 2007

Sulodexide induces hepatocyte growth factor release in humans

scientific article published on 29 December 2006

TGF-β1 and Endothelial/Tissue Injury With High-dose Intravenous Iron Therapy in Renal Failure: Evidence or Perception?

artículo científico publicado en 2006

The hematocrit-corrected erythrocyte sedimentation rate can be useful in diagnosing inflammation in hemodialysis patients

scientific article published on 01 December 2001

The periodontal status of pre-dialysis chronic kidney disease and maintenance dialysis patients

scientific article published on 23 November 2006

Tissue factor and its inhibitor in human non-crescentic glomerulonephritis--immunostaining vs plasma and urinary levels

artículo científico publicado en 2006

Tissue factor and thrombomodulin in hemodialysis patients: associations with endothelial injury, liver disease, and erythropoietin therapy

artículo científico publicado en 2002

Treatment of heparin-induced thrombocytopenia type II in hemodialysis patients: the search for a Holy Grail continues

artículo científico publicado en 2007

Unexpected and striking effect of heparin-free dialysis on cytokine release

artículo científico publicado en 2017

Unexpected effect of haemodialysis on salivary hepatocyte growth factor

scientific article published on 16 September 2005

[Activin A-follistatin: new cytokines, new perspectives]

scientific article published on 01 April 2003

Lista de obras de Jacek Borawski

Activation of hepatocyte growth factor/activin A/follistatin system during hemodialysis: role of heparin

Activin A/follistatin system: another link to heparin-induced osteoporosis?

Altered circadian rhythm of platelet aggregation in hemodialyzed patients

Chronic viral hepatitis C, oxidative stress and the coagulation/fibrinolysis system in haemodialysis patients

Circulating endothelial markers and probability of stroke in haemodialysis patients

Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study

Effect of hemodialysis on plasma levels of vascular endothelial markers

Effect of ketanserin on platelet function and bleeding time in uremic patients treated with erythropoietin.

Effect of sulodexide on plasma transforming growth factor-beta1 in healthy volunteers.

Effects of Enoxaparin on Intravascular Sclerostin Release in Healthy Men.

Effects of enoxaparin on myeloperoxidase release during hemodialysis

Effects of recombinant erythropoietin therapy on circulating endothelial markers in hemodialysis patients.

Endothelial dysfunction marker von Willebrand factor antigen in haemodialysis patients: associations with pre-dialysis blood pressure and the acute phase response

Endothelial injury markers with high-dose intravenous iron therapy in renal failure

Enoxaparin but not unfractionated heparin causes a dose-dependent increase in plasma TGF- 1 during haemodialysis: a cross-over study

Enoxaparin decreases serum MCP-1 concentration during haemodialysis-preliminary report

Evaluation of the thyroid size among school children aged 6-13 with the normal iodine excretion in the urine and the usability of referential values still applied

Extracellular superoxide dismutase release by enoxaparin and sparing effect of heparin-grafted hemodialyzer

Full-length TFPI release by heparinoid sulodexide

Hemoglobin level is an important determinant of acid-base status in hemodialysis patients

Heparin, Myeloperoxidase, and Atherosclerosis

Hepatocyte Growth Factor: A Possible Mediator of Heparin-induced Osteoporosis?

Hepatocyte growth factor in saliva is a potential marker of symptomatic periodontal disease

Hepatocyte growth factor in saliva of patients with renal failure and periodontal disease

Hepatocyte growth factor/activin A/follistatin system activation during hemodialysis with different low molecular weight heparins.

High plasma endostatin level unaffected by low-molecular weight heparin in hemodialysis patients--a preliminary report.

Increased soluble thrombomodulin does not always indicate endothelial injury

Inflammatory markers and platelet aggregation tests as predictors of hemoglobin and endogenous erythropoietin levels in hemodialysis patients

Insulin sensitivity, plasma adiponectin and sICAM-1 concentrations in patients with subclinical hypothyroidism: response to levothyroxine therapy

Intravenous and oral sulodexide versus coagulation activation markers in humans.

Inverse relationships between haemoglobin and ristocetin-induced platelet aggregation in haemodialysis patients under erythropoietin therapy

Is xerostomia a risk factor for cardiovascular morbidity and mortality in maintenance hemodialysis patients?

Ketanserin and erythropoiesis in hemodialysis patients with polycystic kidneys

Liver disease vs systemic inflammation in haemodialysis patients

Long-term effects of erythropoietin on platelet serotonin storage and platelet aggregation in hemodialysis patients with reference to ketanserin treatment.

Modulation of hematopoiesis by ketanserin in erythropoietin-treated uremic patients: evidence from platelet studies

Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: the underestimated modifying effects of heparin.

Myeloperoxidase up-regulation during haemodialysis: is heparin the missing link?

Plasma activin A in hemodialysis patients: does brand of immunoassay matter?

Plasma fibrinogen level is an important determinant of prolonged euglobulin clot lysis time in hemodialysis patients.

Pleiotropic effects of heparin and heparinoids in peritoneal dialysis.

Problems of nephrooncology. Proceedings from the 1st Scientific and Training Conference Nephrooncology 5-6 October 2018, Gdańsk, Poland.

Relations between oxidative stress, hepatocyte growth factor, and liver disease in hemodialysis patients

Relationship between oxidative stress and extrinsic coagulation pathway in haemodialyzed patients

Relevance of some growth factors to cardiovascular disease in maintenance hemodialysis patients

Renal function, proteinuria and ACE‐inhibitor therapy as determinants of plasma levels of endothelial markers

SEN virus infection in maintenance hemodialysis patients

Salivary phosphate-binding chewing gum--an integrative approach to chronic kidney disease and oral diseases

Serum alpha1-antitrypsin but not complement C3 and C4 predicts chronic inflammation in hemodialysis patients

Serum hepatocyte growth factor is associated with viral hepatitis, cardiovascular disease, erythropoietin treatment, and type of heparin in haemodialysis patients.

Short-term Erythropoietin Therapy Does Not Increase Plasma Tissue Factor and its Inhibitor Levels in Hemodialysis Patients

Staphylococcal scalded skin syndrome in the course of lupus nephritis

Striking increase in circulating hepatocyte growth factor during enoxaparin-anticoagulated haemodialysis

Sulodexide for hemodialysis anticoagulation in heparin-induced thrombocytopenia type II.

Sulodexide induces hepatocyte growth factor release in humans

TGF-β1 and Endothelial/Tissue Injury With High-dose Intravenous Iron Therapy in Renal Failure: Evidence or Perception?

The hematocrit-corrected erythrocyte sedimentation rate can be useful in diagnosing inflammation in hemodialysis patients

The periodontal status of pre-dialysis chronic kidney disease and maintenance dialysis patients

Tissue factor and its inhibitor in human non-crescentic glomerulonephritis--immunostaining vs plasma and urinary levels

Tissue factor and thrombomodulin in hemodialysis patients: associations with endothelial injury, liver disease, and erythropoietin therapy

Treatment of heparin-induced thrombocytopenia type II in hemodialysis patients: the search for a Holy Grail continues

Unexpected and striking effect of heparin-free dialysis on cytokine release

Unexpected effect of haemodialysis on salivary hepatocyte growth factor

[Activin A-follistatin: new cytokines, new perspectives]